Menu Search
Equities

AstraZeneca PLC

AZN:LSE

AstraZeneca PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)12,110.00
  • Today's Change-56.00 / -0.46%
  • Shares traded1.60m
  • 1 Year change+1.56%
  • Beta0.3704
Data delayed at least 15 minutes, as of May 17 2024 16:51 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 16-May-24
Select bar for recommendation details.
Recommendations16-May-24
Buy9
Outperform16
Hold5
Underperform1
Sell0

Share price forecast in USD

The 27 analysts offering 12 month price targets for AstraZeneca plc have a median target of 13,283.21, with a high estimate of 17,678.15 and a low estimate of 6,141.25. The median estimate represents a 9.69% increase from the last price of 12,110.00.
High46.0%17,678.15
Med9.7%13,283.21
Low-49.3%6,141.25

Dividends in USD

In 2023, AstraZeneca PLC reported a dividend of 2.90 USD, equaling last years dividend. The 22 analysts covering the company expect dividends of 3.10 USD for the upcoming fiscal year, an increase of 7.05%.
Div growth (TTM)0.21%
More ▼

Earnings history & estimates in USD

On Apr 25, 2024, AstraZeneca plc reported 1st quarter 2024 earnings of 2.06 per share. This result exceeded the 1.91 consensus of the 12 analysts covering the companyand exceeded last year's 1st quarter results by 7.29%.
The next earnings announcement is expected on Jul 25, 2024.
Average growth rate+4.58%
AstraZeneca plc reported annual 2023 earnings of 7.26 per share on Feb 08, 2024.
Average growth rate+20.34%
More ▼

Revenue history & estimates in USD

AstraZeneca PLC had 1st quarter 2024 revenues of 12.68bn. This bettered the 11.81bn consensus of the 13 analysts covering the company. This was 16.55% above the prior year's 1st quarter results.
Average growth rate+3.92%
AstraZeneca PLC had revenues for the full year 2023 of 45.81bn. This was 3.29% above the prior year's results.
Average growth rate+17.89%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.